Skip to Content
Merck
  • Effects of clonidine and methylphenidate on motor activity in Fmr1 knockout mice.

Effects of clonidine and methylphenidate on motor activity in Fmr1 knockout mice.

Neuroscience letters (2014-11-30)
Craige C Wrenn, Andrew M Heitzer, Alexandra K Roth, Lauren Nawrocki, Maria G Valdovinos
ABSTRACT

Fragile X syndrome (FXS), a disorder caused by a mutation in the FMR1 gene, is often associated with Attention Deficit Hyperactivity Disorder (ADHD). Common treatments for the hyperactivity often seen in ADHD involve the use of stimulants and α2-adrenergic agonists. The Fmr1 knockout (KO) mouse has been found to be a valid model for FXS both biologically and behaviorally. Of particular interest to our research, the Fmr1 KO mouse has been demonstrated to show increased locomotion in comparison to wild type (WT) littermates. In the present study, we assessed the effects of clonidine (0.05 mg/kg) and methylphenidate (5 mg/kg) on motor activity in Fmr1 KO mice and their WT littermates in the open field test. Results showed that methylphenidate increased motor activity in both genotypes. Clonidine decreased motor activity in both genotypes, but the effect was delayed in the Fmr1 KO mice.

MATERIALS
Product Number
Brand
Product Description

Clonidine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Benzoylecgonine-d3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Benzoylecgonine-d3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Methylphenidate hydrochloride
Sigma-Aldrich
Clonidine hydrochloride, solid